LEADER 04478nam 2201045z- 450 001 9910557781603321 005 20231214133204.0 035 $a(CKB)5400000000045573 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76798 035 $a(EXLCZ)995400000000045573 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMultimodal Therapy of Upper Gastrointestinal Malignancies 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (272 p.) 311 $a3-0365-0920-8 311 $a3-0365-0921-6 330 $aRecent decades have seen remarkable advances in the treatment of upper gastrointestinal malignancies, i.e., adenocarcinoma and squamous cell carcinoma as well as gastrointestinal stromal and other rare tumors of the esophagus and stomach. While, historically, surgical resection has been the sole treatment for these tumors, multimodal therapies have meanwhile proven their efficacy. At present, pre- and postoperative chemotherapy and radiotherapy, targeted drug therapy, and stage-specific surgical approaches are all indispensable cornerstones of an individualized treatment for upper gastrointestinal malignancies. With such multimodal treatment, better outcomes comprising improved quality of life and prolonged survival have been achieved for patients. However, for many tumor entities and stages, the ideal combination and sequence of treatments is still being evaluated in clinical trials. Moreover, the value of novel approaches such as immunotherapy or robotic surgery remains a matter of research. In this Special Issue of Cancers, up-to-date original research, short communications, and comprehensive review articles on all modalities playing a role in the treatment of upper gastrointestinal malignancies have been published. 606 $aPublic health & preventive medicine$2bicssc 610 $agastric cancer 610 $agastrectomy 610 $acomplications 610 $aoutcome 610 $asurvival 610 $alymph node ratio 610 $aneoadjuvant chemotherapy 610 $aconversion surgery 610 $acancer dormancy 610 $anuclear receptor NR2F1 610 $aclinical pathways 610 $agastric surgery 610 $aoncological gastrectomy 610 $aquality of care 610 $aoutcomes 610 $astandardization 610 $aadjuvant therapy 610 $agastrointestinal tract 610 $agenetic diagnosis 610 $aradiosensitivity 610 $amortality 610 $afailure to rescue 610 $aimmunotherapy 610 $agenetics 610 $aesophageal cancer 610 $amultidisciplinary 610 $agastric/gastroesophageal cancer 610 $aperioperative chemotherapy 610 $aoverall survival 610 $arelapse-free survival 610 $askeletal muscle index 610 $aesophagectomy 610 $anutritional status 610 $asarcopenia 610 $aesophageal anastomosis 610 $aminimally invasive surgery 610 $ainduction chemotherapy 610 $achemo-radiotherapy 610 $aneoadjuvant treatment 610 $aesophageal squamous cell carcinoma 610 $amultimodal treatment 610 $aneoadjuvant chemoradiotherapy 610 $adefinitive chemoradiotherapy 610 $aLauren histotype 610 $agastrointestinal stromal tumor 610 $aneuroendocrine tumor 610 $aMALT lymphoma 610 $amucosal resection 610 $asubmucosal dissection 610 $aGIST 610 $astomach 610 $aneoadjuvant therapy 610 $aimatinib 610 $aorgan preservation 610 $asquamous cell esophageal cancer 610 $agastro-esophageal reflux disease 610 $aBarrett's esophagus 610 $aearly adenocarcinoma of esophagus 610 $aendoscopic submucosal dissection 610 $aendoscopic mucosal resection 615 7$aPublic health & preventive medicine 700 $aRonellenfitsch$b Ulrich$4edt$01309877 702 $aRonellenfitsch$b Ulrich$4oth 906 $aBOOK 912 $a9910557781603321 996 $aMultimodal Therapy of Upper Gastrointestinal Malignancies$93029691 997 $aUNINA